AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1920175 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise training (five 45 min sessions/week, brisk walking at 62 beta +/‐ 2% VO2max for 15 weeks)
Number of subjects: 35
Study 1920175 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise training
Number of subjects: 35
Study 1920175 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise (NEX)
Number of subjects: 35
Study 7082779 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) 50 mg administered concurrently with propranolol
Number of subjects: 0
Study 7082779 — intervention group
Group type: EXPERIMENTAL
Intervention: INDERIDE (40/25 mg)
Number of subjects: 0
Study 7082779 — intervention group
Group type: EXPERIMENTAL
Intervention: INDERIDE (80/25 mg)
Number of subjects: 0
Study 7082779 — intervention group
Group type: COMPARATOR
Intervention: Reference formulations (separate tablets of INDERAL plus HYDRODIURIL)
Number of subjects: 0
Study 31788697 — intervention group
Group type: EXPERIMENTAL
Intervention: High intrinsic iodine milk (IIM)
Number of subjects: 12
Study 31788697 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrinsically added iodine in milk (EIM)
Number of subjects: 12
Study 31788697 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous iodine solution (AIS)
Number of subjects: 12
Study 31788697 — intervention group
Group type: COMPARATOR
Intervention: All conditions (IIM, EIM, AIS)
Number of subjects: 12
Study 28554458 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-borne appliance
Number of subjects: 47
Study 28554458 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-borne appliance
Number of subjects: 47
Study 28554458 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid appliance
Number of subjects: 47
Study 25800247 — intervention group
Group type: EXPERIMENTAL
Intervention: Early support
Number of subjects: 150
Study 25800247 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 25800247 — intervention group
Group type: EXPERIMENTAL
Intervention: Late support
Number of subjects: 150
Study 24932858 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care (IC) program
Number of subjects: 66
Study 24932858 — intervention group
Group type: COMPARATOR
Intervention: Rational Rehabilitation (RR) program
Number of subjects: 66
Study 23217219 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (15-minute session)
Number of subjects: 87
Study 23217219 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 87
Study 18948412 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-0777 (sphingosine 1-phosphate receptor-1 modulator)
Number of subjects: 0
Study 18075468 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 0
Study 15561647 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin <1800 mg/d
Number of subjects: 603
Study 15561647 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin >=1800 mg/d
Number of subjects: 603
Study 15561647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study 11379678 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 124
Study 11379678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with 5 microg fentanyl
Number of subjects: 124
Study 11379678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with 15 microg fentanyl
Number of subjects: 124
Study 11379678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with 25 microg fentanyl
Number of subjects: 124
Study 9229060 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mothers' programme (intervention group)
Number of subjects: 39
Study 9229060 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mothers' programme (traveller children)
Number of subjects: 39
Study 9229060 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet of traveller children
Number of subjects: 39
Study 9229060 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet of traveller mothers
Number of subjects: 39
Study 9229060 — intervention group
Group type: EXPERIMENTAL
Intervention: Traveller and RCT intervention mothers
Number of subjects: 39
Study 9229060 — intervention group
Group type: COMPARATOR
Intervention: Settled control mothers
Number of subjects: 39
Study 8433726 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 142
Study 8433726 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate coronary angioplasty
Number of subjects: 142
Study 3676923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 66
Study 3676923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 29322315 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate
Number of subjects: 9
Study 29322315 — intervention group
Group type: COMPARATOR
Intervention: Intact casein
Number of subjects: 9
Study 28318138 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month dual antiplatelet therapy (DAPT)
Number of subjects: 907
Study 28318138 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month dual antiplatelet therapy (DAPT)
Number of subjects: 907
Study 25678217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen drops (1 drop every 12 hours) with placebo pills (2 pills daily)
Number of subjects: 140
Study 25678217 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops with ketotifen pills (2 pills daily)
Number of subjects: 140
Study 23812961 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of atomoxetine hydrochloride capsules (40 mg)
Number of subjects: 22
Study 23812961 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of atomoxetine hydrochloride capsules (40 mg)
Number of subjects: 22
Study 21861888 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus bevacizumab (Cape-Bev) - capecitabine 1250 mg/m² bid for 14 days plus bevacizumab 7.5 mg/kg q3w
Number of subjects: 0
Study 21861888 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) - capecitabine 800 mg/m² bid for 14 days, irinotecan 200 mg/m² on day 1, and bevacizumab 7.5 mg/kg q3w
Number of subjects: 0
Study 19751325 — intervention group
Group type: EXPERIMENTAL
Intervention: Double cervical cerclage
Number of subjects: 51
Study 19751325 — intervention group
Group type: COMPARATOR
Intervention: Traditional single cervical cerclage
Number of subjects: 51
Study 17920092 — intervention group
Group type: EXPERIMENTAL
Intervention: Argemone mexicana decoction, Group A: once daily for 3 days, n=23
Number of subjects: 80
Study 17920092 — intervention group
Group type: EXPERIMENTAL
Intervention: Argemone mexicana decoction, Group B: twice daily for 7 days, n=40
Number of subjects: 80
Study 17920092 — intervention group
Group type: EXPERIMENTAL
Intervention: Argemone mexicana decoction, Group C: four times daily for the first 4 days followed by twice daily for 3 days, n=17
Number of subjects: 80
Study 17920092 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response in children aged <1 year
Number of subjects: 80
Study 17920092 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response in patients aged >5 years
Number of subjects: 80
Study 17920092 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ACR at Day 14
Number of subjects: 80
Study 17920092 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects observed
Number of subjects: 80
Study 15151520 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-methadone
Number of subjects: 59
Study 15151520 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-methadone
Number of subjects: 59
Study 11393876 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle feedback with instructions
Number of subjects: 4
Study 11393876 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle feedback without instructions
Number of subjects: 4
Study 11393876 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb feedback with instructions
Number of subjects: 4
Study 11393876 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb feedback without instructions
Number of subjects: 4
Study 9821899 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric-Eccentric Resistance Training
Number of subjects: 16
Study 8624291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (50 mg/m2, repeated courses every 28 days for 6 cycles)
Number of subjects: 271
Study 8624291 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 271
Study 2665423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytobrush and Ayre spatula
Number of subjects: 205
Study 2665423 — intervention group
Group type: COMPARATOR
Intervention: Extended-tip spatula
Number of subjects: 205
Study 1096922 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental drugs (various local anaesthetic agents)
Number of subjects: 1
Study 1096922 — intervention group
Group type: COMPARATOR
Intervention: Standard local anaesthetic agent
Number of subjects: 1
Study 30371145 — intervention group
Group type: EXPERIMENTAL
Intervention: Insult (verbal behaviour designed to offend and upset the performer)
Number of subjects: 0
Study 30371145 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction (verbal behaviour designed to draw attention away from the task)
Number of subjects: 0
Study 30371145 — intervention group
Group type: COMPARATOR
Intervention: Control (neutral verbal behaviour)
Number of subjects: 0
Study 30371145 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect of verbal antisocial behaviour
Number of subjects: 0
Study 27435295 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX-PG concentrations in erythrocytes
Number of subjects: 98
Study 27435295 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX-PG1-5 > 50.6 nM at 8 weeks
Number of subjects: 98
Study 27435295 — intervention group
Group type: COMPARATOR
Intervention: MTX-PG1-5 ≤ 50.6 nM at 8 weeks
Number of subjects: 98
Study 25554994 — intervention group
Group type: EXPERIMENTAL
Intervention: sertraline
Number of subjects: 339
Study 25554994 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram
Number of subjects: 339
Study 25554994 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine extended-release
Number of subjects: 339
Study 25554994 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-melancholic patients)
Number of subjects: 339
Study 23185988 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive care management
Number of subjects: 219
Study 23185988 — intervention group
Group type: EXPERIMENTAL
Intervention: Time between respiratory symptoms onset and ICU admission > 2 days
Number of subjects: 219
Study 23185988 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 219
Study 23185988 — intervention group
Group type: EXPERIMENTAL
Intervention: More than one line of chemotherapy
Number of subjects: 219
Study 23185988 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen flow at admission
Number of subjects: 219
Study 23185988 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-respiratory symptoms
Number of subjects: 219
Study 23185988 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic organ dysfunction (LOD) score at admission
Number of subjects: 219
Study 22027749 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocet (60 mg/m intravenously on day 1 every 4 weeks)
Number of subjects: 18
Study 19392956 — intervention group
Group type: EXPERIMENTAL
Intervention: Toileting assistance every 2 hours for 2 days
Number of subjects: 111
Study 19392956 — intervention group
Group type: COMPARATOR
Intervention: Usual NH care
Number of subjects: 111
Study 17597524 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical neurostimulation (5 minutes before plus 1 minute during the first episode)
Number of subjects: 60
Study 17597524 — intervention group
Group type: COMPARATOR
Intervention: Electrical neurostimulation (5 minutes before plus 1 minute during the second episode)
Number of subjects: 60
Study 15142030 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g carbohydrate (CHO)/kg body mass carbohydrate beverage (25% solution)
Number of subjects: 15
Study 15142030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11517127 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO therapy (100 U x kg(‐1) s.c. three times a week for 3 weeks before surgery and i.v. on the day of surgery)
Number of subjects: 39
Study 11517127 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched patients who underwent open heart surgery during the two preceding years)
Number of subjects: 39
Study 9663725 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus azithromycin and amoxycillin (OAzA group: n = 50)
Number of subjects: 100
Study 9663725 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole plus azithromycin and metronidazole (OAzM group: n = 50)
Number of subjects: 100
Study 9663725 — intervention group
Group type: EXPERIMENTAL
Intervention: OAzA group
Number of subjects: 100
Study 9663725 — intervention group
Group type: COMPARATOR
Intervention: OAzM group
Number of subjects: 100
Study 8114860 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir for 7 days with prednisolone
Number of subjects: 400
Study 8114860 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir for 7 days with placebo
Number of subjects: 400
Study 8114860 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir for 21 days with prednisolone
Number of subjects: 400
Study 8114860 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir for 21 days with placebo
Number of subjects: 400
Study 2629624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal based oral rehydration solution (made of maize, millet, sorghum, or rice)
Number of subjects: 257
Study 2629624 — intervention group
Group type: COMPARATOR
Intervention: World Health Organisation/United Nations Childrens Fund (WHO/Unicef) recommended oral rehydration solution
Number of subjects: 257
Study 786421 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram implants
Number of subjects: 0
Study 786421 — intervention group
Group type: COMPARATOR
Intervention: Sham operations
Number of subjects: 0
Study 31236778 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB) with catheter (Group I, n=350 patients)
Number of subjects: 511
Study 31236778 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular analgesic infusion (IAC) (Group II, n=172 patients)
Number of subjects: 511
Study 29196485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (multicomponent obesity prevention programme)
Number of subjects: 1640
Study 29196485 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control arm)
Number of subjects: 1640
Study 29196485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 1640
Study 25849623 — intervention group
Group type: EXPERIMENTAL
Intervention: FEP without cannabis misuse
Number of subjects: 81
Study 25849623 — intervention group
Group type: COMPARATOR
Intervention: FEP with cannabis misuse
Number of subjects: 81
Study 23757614 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vitamin C (250 mg/day)
Number of subjects: 8
Study 23757614 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose vitamin C (500 mg/day)
Number of subjects: 8
Study 23757614 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin C (1,000 mg/day)
Number of subjects: 8
Study 23757614 — intervention group
Group type: COMPARATOR
Intervention: No supplemental vitamin C
Number of subjects: 8
Study 23757614 — intervention group
Group type: EXPERIMENTAL
Intervention: High-caloric content meal
Number of subjects: 8
Study 23757614 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (all dosages)
Number of subjects: 8
Study 16441729 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive periodontitis (AP) subjects
Number of subjects: 39
Study 16441729 — intervention group
Group type: COMPARATOR
Intervention: Periodontally healthy individuals (PH)
Number of subjects: 39
Study 14623488 — intervention group
Group type: EXPERIMENTAL
Intervention: 100ml of bottled drinking water with 0.4mg of copper (Cu)
Number of subjects: 269
Study 14623488 — intervention group
Group type: EXPERIMENTAL
Intervention: 150ml of bottled drinking water with 0.8mg of copper (Cu)
Number of subjects: 269
Study 14623488 — intervention group
Group type: EXPERIMENTAL
Intervention: 200ml of bottled drinking water with 1.2mg of copper (Cu)
Number of subjects: 269
Study 14623488 — intervention group
Group type: COMPARATOR
Intervention: 200ml of bottled drinking water with 0mg of copper (Cu)
Number of subjects: 269
Study 14623488 — intervention group
Group type: EXPERIMENTAL
Intervention: 200ml of bottled drinking water with 1.6mg of copper (Cu)
Number of subjects: 269
Study 10493218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 0
Study 10493218 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 0
Study 10493218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac and Dalteparin
Number of subjects: 0
Study 8710963 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching group
Number of subjects: 39
Study 8710963 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 1677695 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Number of subjects: 0
Study 1677695 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy plus breast irradiation
Number of subjects: 0
Study 1677695 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mastectomy
Number of subjects: 0
Study 6354933 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times daily (t.i.d.)
Number of subjects: 30
Study 6354933 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg twice daily (b.i.d.)
Number of subjects: 30
Study 6354933 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg three times daily (t.i.d.)
Number of subjects: 30
Study 6354933 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily (b.i.d.)
Number of subjects: 30
Study 6354933 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times daily (t.i.d.) with chlorthalidone 25 mg daily
Number of subjects: 30
Study 6354933 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg twice daily (b.i.d.) with chlorthalidone 25 mg daily
Number of subjects: 30
Study 31875936 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline UA levels < 5.0 mg/dL
Number of subjects: 279
Study 31875936 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline UA levels 5.0-6.0 mg/dL
Number of subjects: 279
Study 31875936 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline UA levels 6.0-7.0 mg/dL
Number of subjects: 279
Study 31875936 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline UA levels ≥ 7.0 mg/dL
Number of subjects: 279
Study 30779295 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25 mg orally three times daily until 32+0 weeks, birth, or fetal death)
Number of subjects: 120
Study 30779295 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 120
Study 30779295 — intervention group
Group type: COMPARATOR
Intervention: Placebo (visually matching placebo three times daily until 32+0 weeks, birth, or fetal death)
Number of subjects: 120
Study 30779295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 29025605 — intervention group
Group type: EXPERIMENTAL
Intervention: CarboFix volar locking plate (Group A)
Number of subjects: 30
Study 29025605 — intervention group
Group type: COMPARATOR
Intervention: Acu-Lock Volar Distal Radius Plate (Group B)
Number of subjects: 30
Study 26280699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated oil and α-bisabolol formulation
Number of subjects: 29
Study 26280699 — intervention group
Group type: COMPARATOR
Intervention: Control cream (vitamin A, vitamin E, talc, and zinc oxide)
Number of subjects: 29
Study 23740278 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume haemofiltration (HVHF) at 70 mL/kg/h
Number of subjects: 140
Study 23740278 — intervention group
Group type: COMPARATOR
Intervention: Standard-volume haemofiltration (SVHF) at 35 mL/kg/h
Number of subjects: 140
Study 21376385 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesilate (1·4 mg/m² administered intravenously during 2‐5 min on days 1 and 8 of a 21‐day cycle)
Number of subjects: 762
Study 21376385 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice (TPC)
Number of subjects: 762
Study 21376385 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 762
Study 21376385 — intervention group
Group type: COMPARATOR
Intervention: TPC
Number of subjects: 762
Study 18193194 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bundle (SB) technique with a 4-stranded semitendinosus (ST) graft
Number of subjects: 50
Study 18193194 — intervention group
Group type: COMPARATOR
Intervention: Double-bundle (DB) technique with a 2-stranded ST graft
Number of subjects: 50
Study 18193194 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (SB and DB)
Number of subjects: 50
Study 16491283 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH(1-34) treatment
Number of subjects: 0
Study 16491283 — intervention group
Group type: COMPARATOR
Intervention: Control group (quadruple-labeled without hPTH(1-34))
Number of subjects: 0
Study 14678901 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic cardiopulmonary bypass (CPB, study group, n=20)
Number of subjects: 40
Study 14678901 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic cardiopulmonary bypass (control group, n=20)
Number of subjects: 40
Study 11314498 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet treatment
Number of subjects: 105
Study 11314498 — intervention group
Group type: COMPARATOR
Intervention: Nonhelmet treatment
Number of subjects: 105
Study 8857040 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bile salts (500 mg of sodium deoxycholate 8-hourly for 48 hours preoperatively)
Number of subjects: 16
Study 8857040 — intervention group
Group type: COMPARATOR
Intervention: Bile refeeding (total bile output for the entire period of biliary drainage, median 13 days)
Number of subjects: 16
Study 10148188 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf blood dialysate
Number of subjects: 60
Study 10148188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6527988 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 to 5 min of behavioral cessation counseling
Number of subjects: 0